Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6248 posts found.

FDA approves Roche’s HPV self-collection screening option

May 15, 2024 Medical Communications FDA, HPV, Oncology, Roche, cervical cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …
News

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024 Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).
News

Moderna shares update on RSV vaccine

May 13, 2024 Medical Communications FDA, Immunology, Moderna, Vaccine

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review …
News

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024 Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
News

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024 Medical Communications COPD, Cardiology, clinical trial, verona pharma

Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …
News
anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024 Medical Communications FDA, Haematology, Pfizer, haemophilia

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …
News

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

April 29, 2024 Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …
News

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024 Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism

Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …
News

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024 Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …
News

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024 Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer

ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …
News

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024 Medical Communications Emblaveo, European Commission, Immunology, Pfizer

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult …
News

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024 Medical Communications FDA, Oncology, Roche, lung cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …
News

GSK’s meningococcal vaccine candidate accepted for FDA review

April 16, 2024 Medical Communications FDA, GSK, Immunology, meningococcal

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …
News

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024 Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
News

Baxter expands US portfolio with new injectables

April 12, 2024 Medical Communications Pharmacy, baxter, injectables, product launch

Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in …
News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024